胰岛素增敏剂在非酒精性脂肪肝病中的应用

被引：6

作者：

郭春

黄建权

王观春

机构：

[1] 航天中心医院

来源：

药品评价 | 2013年 / 10卷 / 01期

关键词：

非酒精性脂肪肝病; 胰岛素增敏剂; 二甲双胍; 罗格列酮; 吡格列酮;

D O I：

暂无

中图分类号：

R575.5 [肝代谢障碍];

学科分类号：

100201 [内科学];

摘要：

<正>脂肪肝是肝脏脂肪代谢异常的一种疾病,其发生与酗酒、肥胖、糖尿病、脂质代谢异常及一些药物应用有关。脂肪肝可分为2大类[1],酒精性脂肪肝病(AFLD,仅占7.2%)与饮酒有关,而非酒精性脂肪肝病(NAFLD,占72.8%)是指除外酒精和其他明确的肝损害因素所致的,以弥漫性肝细胞大疱性脂肪变性为病理

引用

收藏

页码：15 / 20

页数：6

相关论文

共 20 条

[1]

Rosiglitazone Versus Rosiglitazone and Metformin Versus Rosiglitazone and Losartan in the Treatment of Nonalcoholic Steatohepatitis in Humans: A 12-Month Randomized, Prospective, Open-Label Trial [J].

Torres, Dawn M. ;

Jones, Frances J. ;

Shaw, Janet C. ;

Williams, Christopher D. ;

Ward, John A. ;

Harrison, Stephen A. .

HEPATOLOGY, 2011, 54 (05) :1631-1639

[2]

Long-Term Efficacy of Rosiglitazone in Nonalcoholic Steatohepatitis: Results of the Fatty Liver Improvement by Rosiglitazone Therapy (FLIRT 2) Extension Trial [J].

Ratziu, Vlad ;

Charlotte, Frederic ;

Bernhardt, Carole ;

Giral, Philippe ;

Halbron, Marine ;

LeNaour, Gilles ;

Hartmann-Heurtier, Agnes ;

Bruckert, Eric ;

Poynard, Thierry .

HEPATOLOGY, 2010, 51 (02) :445-453

[3]

Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease [J].

Omer, Ziya ;

Cetinkalp, Sevki ;

Akyildiz, Murat ;

Yilmaz, Funda ;

Batur, Yucel ;

Yilmaz, Candeger ;

Akarca, Ulus .

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2010, 22 (01) :18-23

[4]

The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease [J].

Nar, A. ;

Gedik, O. .

ACTA DIABETOLOGICA, 2009, 46 (02) :113-118

[5]

Metformin use in children with nonalcoholic fatty liver disease: An open-label, 24-month, observational pilot study [J].

Nobili, Valerio ;

Manco, Melania ;

Ciampalini, Paolo ;

Alisi, Anna ;

Devito, Rita ;

Bugianesi, Elisabetta ;

Marcellini, Matilde ;

Marchesini, Giulio .

CLINICAL THERAPEUTICS, 2008, 30 (06) :1168-1176

[6]

Rosiglitazone for nonalcoholic steatohepatitis: One-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial [J].

Ratziu, Vlad ;

Giral, Philippe ;

Jacqueminet, Sophie ;

Charlotte, Frederic ;

Hartemann-Heurtier, Agnes ;

Serfaty, Lawrence ;

Podevin, Philippe ;

Lacorte, Jean-Marc ;

Bernhardt, Carole ;

Bruckert, Eric ;

Grimaldi, Andre ;

Poynard, Thierry .

GASTROENTEROLOGY, 2008, 135 (01) :100-110

[7]

Non-alcoholic fatty liver disease: The mist gradually clears.[J].Nimantha Mark Wilfred de Alwis;Christopher Paul Day.Journal of Hepatology.2008,

[8]

A Pilot Study of Vitamin E Versus Vitamin E and Pioglitazone for the Treatment of Nonalcoholic Steatohepatitis [J].

Sanyal, Arun J. ;

Mofrad, Pouneh S. ;

Contos, Melissa J. ;

Sargeant, Carol ;

Luketic, Velimir A. ;

Sterling, Richard K. ;

Stravitz, R. Todd ;

Shiffman, Mitchell L. ;

Clore, John ;

Mills, Alan S. .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2004, 2 (12) :1107-1115

[9]

Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone [J].

Neuschwander-Tetri, BA ;

Brunt, EM ;

Wehmeier, KR ;

Oliver, D ;

Bacon, BR .

HEPATOLOGY, 2003, 38 (04) :1008-1017

[10]

Interim results of a pilot study demonstrating the early effects of the PPAR-γ ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis [J].

Neuschwander-Tetri, BA ;

Brunt, EM ;

Wehmeier, KR ;

Sponseller, CA ;

Hampton, K ;

Bacon, BR .

JOURNAL OF HEPATOLOGY, 2003, 38 (04) :434-440